Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Robles, L; Gravalos, C; Garcia-Alfonso, P; Pachon, V; Longo, F; Martinez, V; Blanco, C; Iglesias, I; Sanjurjo, M; Lopez-Fernandez, LA.

Identification of new SNPs associated with severe toxicity to capecitabine

PHARMACOLOGICAL RESEARCH. 2017; 120: 133-137 Nº de citas: 43 [doi:10.1016/j.phrs.2017.03.021]

Gonzalez-Cao, M; Arance, A; Piulats, JM; Marquez-Rodas, I; Manzano, JL; Berrocal, A; Crespo, G; Rodriguez, D; Perez-Ruiz, E; Berciano, M; Soria, A; Castano, AG; Espinosa, E; Montagut, C; Alonso, L; Puertolas, T; Aguado, C; Royo, MA; Blanco, R; Rodriguez, JF; Munoz, E; Mut, P; Barron, F; Martin-Algarra, S; Spanish Melanoma Grp.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(6): 761-768 Nº de citas: 8 [doi:10.1007/s12094-016-1602-1]

Aapro, M; De Laurentiis, M; Rea, D; Rocha, JEB; Elizalde, R; Landherr, L; Linderholm, B; Mamounas, E; Markopoulos, C; Neven, P; Petrovsky, A; Rouzier, R; Smit, V; Svedman, C; Schneider, D; Thomssen, C; Martin, M.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

BREAST. 2017; 33: 191-199 Nº de citas: 4 [doi:10.1016/j.breast.2017.01.012]

Provencio, M; Sabin, P; Gomez-Codina, J; Torrente, M; Calvo, V; Llanos, M; Guma, J; Quero, C; Blasco, A; Cruz, MA; Aguiar, D; Garcia-Arroyo, F; Lavernia, J; Martinez, N; Morales, M; Saez-Cusi, A; Rodriguez, D; de la Cruz, L; Sanchez, JJ; Rueda, A; GOTEL Spanish Lymphoma Oncology Gr.

Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry

PLoS One. 2017; 12(5): Nº de citas: 20 [doi:10.1371/journal.pone.0177204]

del Alba, AG; Arranz, JA; Puente, J; Mendez-Vidal, MJ; Gallardo, E; Grande, E; Perez-Valderrama, B; Gonzalez-Billalabeitia, E; Lazaro-Quintela, M; Pinto, A; Lainez, N; Piulats, JM; Esteban, E; Rey, JPM; Garcia, JA; Suarez, C.

Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017; 113: 171-190 Nº de citas: 20 [doi:10.1016/j.critrevonc.2017.03.010]

Puente, J; Grande, E; Medina, A; Maroto, P; Lainez, N; Arranz, JA.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

Therapeutic Advances in Medical Oncology. 2017; 9(5): 307-318 Nº de citas: 49 [doi:10.1177/1758834017692779]

Jimenez-Fonseca, P; Carmona-Bayonas, A; Lorenzo, MLS; Plazas, JG; Custodio, A; Hernandez, R; Garrido, M; Garcia, T; Echavarria, I; Cano, JM; Palomo, AR; Mangas, M; Declara, IM; Ramchandani, A; Visa, L; Viudez, A; Buxo, E; Diaz-Serrano, A; Lopez, C; Azkarate, A; Longo, F; Castanon, E; Bayona, RS; Pimentel, P; Limon, ML; Cerda, P; Llosa, RA; Serrano, R; Lobera, MPF; Alsina, M; Nuno, A; Gomez-Martin, C.

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Gastric Cancer. 2017; 20(3): 465-474 Nº de citas: 18 [doi:10.1007/s10120-016-0639-8]

Garcia-Donas, J; Font, A; Perez-Valderrama, B; Virizuela, JA; Climent, MA; Hernando-Polo, S; Arranz, JA; Llorente, MD; Lainez, N; Villa-Guzman, JC; Mellado, B; del Alba, AG; Castellano, D; Gallardo, E; Anido, U; del Muro, XG; Domenech, M; Puente, J; Morales-Barrera, R; Perez-Gracia, JL; Bellmunt, J.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

LANCET ONCOLOGY. 2017; 18(5): 672-681 Nº de citas: 45 [doi:10.1016/S1470-2045(17)30242-5]

Gonzalez-Billalabeitia, E; Sepulveda, JM; Maroto, P; Aparicio, J; Arranz, JA; Esteban, E; Girones, R; Lopez-Brea, M; Mendez-Vidal, MJ; Pinto, A; Sastre, J; de Prado, DS; Terrasa, J; Vazquez, S; Powles, T; Beyer, J; Castellano, D; del Muro, XG; Spanish Germ Cell Canc Grp; Spanish Oncology Genitourinary Grp.

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

European Urology Focus. 2017; 3(2-3): 280-286 [doi:10.1016/j.euf.2016.07.002]

Climent, MA; Torregrosa, MD; Vazquez, S; Girones, R; Arranz, JA.

Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

CANCER TREATMENT REVIEWS. 2017; 55: 173-180 Nº de citas: 4 [doi:10.1016/j.ctrv.2017.03.007]

Rivera, F; Andres, R; Felip, E; Garcia-Campelo, R; Lianes, P; Llombart, A; Piera, JM; Puente, J; Rodriguez, CA; Vera, R; Virizuela, JA; Martin, M; Garrido, P.

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(4): 508-518 Nº de citas: 11 [doi:10.1007/s12094-016-1595-9]

Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Munoz, M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Oncotarget. 2017; 8(13): 21930-21937 Nº de citas: 16 [doi:10.18632/oncotarget.15748]

Lope, V; Martin, M; Castello, A; Casla, S; Ruiz, A; Baena-Canada, JM; Casas, AM; Calvo, L; Bermejo, B; Munoz, M; Ramos, M; de Juan-Ferre, A; Jara, C; Anton, A; Jimeno, MA; Lluch, A; Antolin, S; Garcia-Saenz, JA; Estevez, P; Arriola-Arellano, E; Gavila, J; Perez-Gomez, B; Carrasco, E; Pollan, M.

Physical activity and breast cancer risk by pathological subtype

GYNECOLOGIC ONCOLOGY. 2017; 144(3): 577-585 Nº de citas: 28 [doi:10.1016/j.ygyno.2016.12.014]

Sharma, P; Retz, M; Siefker-Radtke, A; Baron, A; Necchi, A; Bedke, J; Plimack, ER; Vaena, D; Grimm, MO; Bracarda, S; Arranz, JA; Pal, S; Ohyama, C; Saci, A; Qu, XT; Lambert, A; Krishnan, S; Azrilevich, A; Galsky, MD.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

LANCET ONCOLOGY. 2017; 18(3): 312-322 Nº de citas: 1388 [doi:10.1016/S1470-2045(17)30065-7]

Salvador, J; Urtasun, JA; Duart, FJB; Garcia-Campelo, R; Carbonero, RG; Lianes, P; Llombart, A; Casado, DI; Piera, JM; Mateu, MM; Puente, J; Rivera, F; Rodriguez, CA; Virizuela, JA; Martin, M; Garrido, P.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(3): 341-356 Nº de citas: 12 [doi:10.1007/s12094-016-1535-8]

Jimenez, MM; Ferrandiz, AC; Urtasun, JA; Garcia-Campelo, R; Gonzalez-Flores, E; Quintela, ML; Mateu, MM; Sanchez, CAR; Bertran, AS; Sanchez, JMS; Garcia, RV; Echaburu, JAV; Palmer, MAS.

New clinical trials regulation in Spain: analysis of royal decree 1090/2015

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(3): 291-300 Nº de citas: 5 [doi:10.1007/s12094-016-1550-9]

de Andres, C; Fernandez-Paredes, L; Tejera-Alhambra, M; Alonso, B; Ramos-Medina, R; Sanchez-Ramon, S.

Activation of Blood CD3(+)CD56(+)CD8(+) T Cells during Pregnancy and Multiple Sclerosis

Frontiers in Immunology. 2017; 8: Nº de citas: 18 [doi:10.3389/fimmu.2017.00196]

Perez-Gracia, JL; Sanmamed, MF; Bosch, A; Patino-Garcia, A; Schalper, KA; Segura, V; Bellmunt, J; Tabernero, J; Sweeney, CJ; Choueiri, TK; Martin, M; Fusco, JP; Rodriguez-Ruiz, ME; Calvo, A; Prior, C; Paz-Ares, L; Pio, R; Gonzalez-Billalabeitia, E; Hernandez, AG; Paez, D; Piulats, JM; Gurpide, A; Andueza, M; de Velasco, G; Pazo, R; Grande, E; Nicolas, P; Abad-Santos, F; Garcia-Donas, J; Castellano, D; Pajares, MJ; Suarez, C; Colomer, R; Montuenga, LM; Melero, I.

Strategies to design clinical studies to identify predictive biomarkers in cancer research

CANCER TREATMENT REVIEWS. 2017; 53: 79-97 Nº de citas: 81 [doi:10.1016/j.ctrv.2016.12.005]